Abstract
Introduction: Anti-resorptive agent-related osteonecrosis of the jaw (ARONJ) is a slowly progressive disease occurring due to the chronic use of antiresorptive agents (e.g., bisphosphonates) and rarely presents with pathologic fractures. The frequency of pathologic fractures is rare, especially in patients with osteoporosis who are prescribed, low-dose bone-modifying agents. Herein, we report a case of rapidly progressive ARONJ with a pathologic fracture in a patient with hemodialysis. Case Report: A 64-year-old woman with hemodialysis due to the microscopic polyangiitis who was treated with corticosteroids, immunosuppressants, and ibandronate presented with tooth pain of left mandibular second premolar and second molar, necessitating extraction. After extraction, ARONJ developed in the left mandibular. Anti-resorptive agent-related osteonecrosis of the jaw progressed rapidly during the follow-up at the 12th and 15th months, furthermore, ARONJ also developed in the right mandibular second premolar and second molar lesion, requiring extensive surgery. We performed curative segmental and marginal mandibulectomy in the left and right hemimandible, respectively. The postoperative course was uneventful. Conclusion: We report a rare case of rapidly progressive ARONJ with pathologic fracture in a patient with hemodialysis. This report suggests a potential role of hemodialysis as a risk factor for disease progression and pathologic fracture development. Further studies regarding factors that inhibit the healing of ARONJ are still needed.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.